Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer

References

• Momenimovahed Z, Tiznobaik A, Taheri S, et al. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287–299.
   PubMed Web of Science ®Google Scholar
• La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev. 2017;26(1):55–62.
   PubMed Web of Science ®Google Scholar
• Luvero D Plotti F, Aloisia A, et al. Ovarian cancer relapse: from the latest scientific evidence to the best practice. Crit Rev Oncol Hematol. 2019;140:28–38.
   PubMed Web of Science ®Google Scholar
• Moufarrij S Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11(1):7.
   PubMed Web of Science ®Google Scholar
• Glasgow MA Argenta P, Abrahante JE, et al. Biological insights into chemotherapy resistance in ovarian cancer. Int J Mol Sci. 2019;20(9):2131 .
   PubMed Web of Science ®Google Scholar
• Ekmann-Gade AW Hogdall CK, Engelholm SA, et al. Neoadjuvant chemotherapy reduces the treatment-free interval after first-line treatment in patients with advanced ovarian cancer. Anticancer Res. 2020;40(5):2765–2770.
   PubMed Web of Science ®Google Scholar
• Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71(3):428–442.
   PubMed Web of Science ®Google Scholar
• Zhang HD Jiang LH, Sun DW, et al. CircRNA: a novel type of biomarker for cancer. Breast Cancer. 2018;25(1):1–7.
   PubMed Web of Science ®Google Scholar
• Chen B, Huang S. Circular RNA: an emerging non-coding RNA as a regulator and biomarker in cancer. Cancer Lett. 2018;418:41–50.
   PubMed Web of Science ®Google Scholar
• Zhao ZJ, Shen J. Circular RNA participates in the carcinogenesis and the malignant behavior of cancer. RNA Biol. 2017;14(5):514–521.
   PubMed Web of Science ®Google Scholar
• Jeyaraman S, Hanif EAM, Ab Mutalib NS, et al. Circular RNAs: potential regulators of treatment resistance in human cancers. Front Genet. 2019;10:1369.
   PubMed Web of Science ®Google Scholar
• Cui C Yang J, Li X, et al. Functions and mechanisms of circular RNAs in cancer radiotherapy and chemotherapy resistance. Mol Cancer. 2020;19(1):58.
   PubMed Web of Science ®Google Scholar
• Zheng S, Wang C, Yan H, et al. Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis. Bioengineered. 2021;12(1):8347–8357.
   PubMed Web of Science ®Google Scholar
• Yan J, Xu H. Regulation of transforming growth factor-beta1 by circANKS1B/miR-515-5p affects the metastatic potential and cisplatin resistance in oral squamous cell carcinoma. Bioengineered. 2021;12(2):12420–12430.
   PubMed Web of Science ®Google Scholar
• Zhang S, Cheng J, Quan C, et al. circCELSR1 (hsa_circ_0063809) contributes to paclitaxel resistance of ovarian cancer cells by regulating FOXR2 expression via miR-1252. Mol Ther Nucleic Acids. 2020;19:718–730.
   PubMedGoogle Scholar
• Zhao Z, Ji M, Wang Q, et al. Circular RNA Cdr1as Upregulates SCAI to suppress cisplatin resistance in ovarian cancer via miR-1270 suppression. Mol Ther Nucleic Acids. 2019;18:24–33.
   PubMedGoogle Scholar
• Xu F, Ni M, Li J, et al. Circ0004390 promotes cell proliferation through sponging miR-198 in ovarian cancer. Biochem Biophys Res Commun. 2020;526(1):14–20.
   PubMed Web of Science ®Google Scholar
• Cao Y, Xie X, Li M, et al. CircHIPK2 contributes to DDP resistance and malignant behaviors of DDP-resistant ovarian cancer cells both in vitro and in vivo through circHIPK2/miR-338-3p/CHTOP ceRNA pathway. Onco Targets Ther. 2021;14:3151–3165.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu Y, Xu X. Knockdown of LncRNA-UCA1 suppresses chemoresistance of pediatric AML by inhibiting glycolysis through the microRNA-125a/hexokinase 2 pathway. J Cell Biochem. 2018;119(7):6296–6308.
   PubMed Web of Science ®Google Scholar
• Wu J, Liu S, Xiang Y, et al. Bioinformatic analysis of circular RNA-Associated ceRNA network associated with hepatocellular carcinoma. Biomed Res Int. 2019;2019:8308694.
   PubMed Web of Science ®Google Scholar
• Song W, Wang W-J, Fu T, et al. Integrated analysis of circular RNA-associated ceRNA network in pancreatic ductal adenocarcinoma. Oncol Lett. 2020;19(3):2175–2184.
   PubMed Web of Science ®Google Scholar
• Das M, Law S. Role of tumor microenvironment in cancer stem cell chemoresistance and recurrence. Int J Biochem Cell Biol. 2018;103:115–124.
   PubMed Web of Science ®Google Scholar
• Cheng S, Huang Y, Lou C, et al. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin beta3/Wnt signaling under miR-137 regulation. Cancer Biol Ther. 2019;20(3):328–337.
   PubMed Web of Science ®Google Scholar
• Huang X, Li Z, Zhang Q, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019;18(1):71.
   PubMed Web of Science ®Google Scholar
• Chen D, Wu X, Zhao J, et al. MicroRNA-634 functions as a tumor suppressor in pancreatic cancer via directly targeting heat shock-related 70-kDa protein 2. Exp Ther Med. 2019;17(5):3949–3956.
   PubMed Web of Science ®Google Scholar
• Zhang CZ, Cao Y, Fu J, et al. miR-634 exhibits anti-tumor activities toward hepatocellular carcinoma via Rab1A and DHX33. Mol Oncol. 2016;10(10):1532–1541.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhang C-D, An J-X, et al. Expression of miR-634 in gastric carcinoma and its effects on proliferation, migration, and invasion of gastric cancer cells. Cancer Med. 2018;7(3):776–787.
   PubMed Web of Science ®Google Scholar
• Peng X, Cao P, He D, et al. MiR-634 sensitizes nasopharyngeal carcinoma cells to paclitaxel and inhibits cell growth both in vitro and in vivo. Int J Clin Exp Pathol. 2014;7(10):6784–6791.
   PubMed Web of Science ®Google Scholar
• van Jaarsveld MT, van Kuijk PF, Boersma AWM, et al. miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer. 2015;14(1):196.
   PubMedGoogle Scholar
• Abbaszadeh Z, Cesmeli S, Biray Avci C. Crucial players in glycolysis: cancer progress. Gene. 2020;726:144158.
   PubMed Web of Science ®Google Scholar
• Wang JJ Siu MK, Jiang YX, et al. Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8(+) T cell function and survival through elevation of PD-L1. Oncoimmunology. 2019;8(11):e1659092.
   PubMed Web of Science ®Google Scholar
• Liu T, Yin H. PDK1 promotes tumor cell proliferation and migration by enhancing the warburg effect in non-small cell lung cancer. Oncol Rep. 2017;37(1):193–200.
   PubMed Web of Science ®Google Scholar
• Qian Y Wu X, Wang H, et al. MicroRNA-4290 suppresses PDK1-mediated glycolysis to enhance the sensitivity of gastric cancer cell to cisplatin. Braz J Med Biol Res. 2020;53(5):e9330.
   PubMed Web of Science ®Google Scholar
• Zhang MCong Q, Zhang XY, et al. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation. J Cell Physiol. 2019;234(5):6361–6370.
   PubMed Web of Science ®Google Scholar